16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus

BMC Medicine

Yehuda Shoenfeld⁵  Joab Chapman²  Edna Mozes³  Juan-Manuel Anaya⁶  Miri Blank¹  Nancy Agmon-Levin¹  Yaron Zafrir¹  Moran Landau-Rabi¹  Maria Teresa Arango⁴  Aviva Katzav²  Shaye Kivity⁷ 

[1] The Zabludovicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, 2 Derech Sheba St., Ramat Gan, 52621, Israel;Department of Neurology, Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, 2 Derech Sheba St., Ramat Gan, 52621, Israel;Department of Immunology, The Weizmann Institute of Science, 234 Herzl Street, Rehovot, 76100, Israel;Doctoral Program in Biomedical Sciences, Universidad del Rosario, Kr 24 N°63C-69, Bogotá, DC, 111221, Colombia;Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Haim Lebanon St., Ramat Aviv, 69978, Israel;Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Kr 24 N°63C-69, Bogotá, DC, 111221, Colombia;Rheumatic Disease Unit, Sheba Medical Center, Tel-Hashomer, 2 Derech Sheba St., Ramat Gan, 52621, Israel

关键词: Cognitive impairment;    Neuropsychiatric lupus;    Anti-DNA;    16/6 idiotype;    Systemic lupus erythematosus;   

Others  :  857117
DOI  :  10.1186/1741-7015-11-90

 received in 2012-09-28, accepted in 2012-12-13,  发布年份 2013

【 摘 要 】

Background

The 16/6-idiotype (16/6-Id) of the human anti-DNA antibody was found to induce experimental lupus in naïve mice, manifested by production of autoantibodies, leukopenia and elevated inflammatory markers, as well as kidney and brain involvement. We assessed behavior and brain pathology of naive mice injected intra-cerebra-ventricularly (ICV) with the 16/6-Id antibody.

Methods

C3H female mice were injected ICV to the right hemisphere with the human 16/6-Id antibody or commercial human IgG antibodies (control). The mice were tested for depression by the forced swimming test (FST), locomotor and explorative activity by the staircase test, and cognitive functions were examined by the novel object recognition and Y-maze tests. Brain slices were stained for inflammatory processes.

Results

16/6-Id injected mice were cognitively impaired as shown by significant differences in the preference for a new object in the novel object recognition test compared to controls (P = 0.012). Similarly, the preference for spatial novelty in the Y-maze test was significantly higher in the control group compared to the 16/6-Id-injected mice (42% vs. 9%, respectively, P = 0.065). Depression–like behavior and locomotor activity were not significantly different between the16/6-Id-injected and the control mice. Immunohistochemistry analysis revealed an increase in astrocytes and microglial activation in the hippocampus and amygdala, in the 16/6-Id injected group compared to the control.

Conclusions

Passive transfer of 16/6-Id antibodies directly into mice brain resulted in cognitive impairments and histological evidence for brain inflammation. These findings shed additional light on the diverse mosaic pathophysiology of neuropsychiatric lupus.

See related Commentary article: http://www.biomedcentral.com/1741-7015/11/91 webcite

【 授权许可】

   
2013 Kivity et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A: The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
• [2]Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, Valdez CR, Escalante A, del Rincon I, Gronseth G, Rhine CB, Padilla P, McGlasson D: Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1214-1220.
• [3]Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, Bleiberg J, Rosenstein D, Pao M, Patronas N, Steele S, Manzano M, van der Veen JW, Lipsky PE, Marenco S, Wesley R, Volpe B, Diamond B, Illei GG: Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2505-2514.
• [4]Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH: Autoantibodies in neuropsychiatric lupus. Autoimmunity 2002, 35:79-86.
• [5]Borchers AT, Aoki CA, Naguwa SM, Keen CL, Shoenfeld Y, Gershwin ME: Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev 2005, 4:329-344.
• [6]The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes Arthritis Rheum 1999, 42:599-608.
• [7]Rekvig OP, Putterman C, Casu C, Gao HX, Ghirardello A, Mortensen ES, Tincani A, Doria A: Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev 2012, 11:596-603.
• [8]Kozora E, Hanly JG, Lapteva L, Filley CM: Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum 2008, 58:3286-3298.
• [9]Kapadia M, Sakic B: Autoimmune and inflammatory mechanisms of CNS damage. Prog Neurobiol 2011, 95:301-333.
• [10]Oikonomou KG, Zachou K, Dalekos GN: Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev 2011, 10:389-396.
• [11]Zandman-Goddard G, Chapman J, Shoenfeld Y: Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007, 36:297-315.
• [12]Weiner SM, Klein R, Berg PA: A longitudinal study of autoantibodies against central nervous system tissue and gangliosides in connective tissue diseases. Rheumatol Int 2000, 19:83-88.
• [13]Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987, 317:265-271.
• [14]Toubi E, Shoenfeld Y: Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007, 6:119-125.
• [15]Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, Chapman J: Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
• [16]DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B: A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189-1193.
• [17]Shoenfeld Y, Isenberg DA, Rauch J, Madaio MP, Stollar BD, Schwartz RS: Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med 1983, 158:718-730.
• [18]Shoenfeld Y, Hsu-Lin SC, Gabriels JE, Silberstein LE, Furie BC, Furie B, Stollar BD, Schwartz RS: Production of autoantibodies by human-human hybridomas. J Clin Invest 1982, 70:205-208.
• [19]Shoenfeld Y, Rauch J, Massicotte H, Datta SK, Andre-Schwartz J, Stollar BD, Schwartz RS: Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. N Engl J Med 1983, 308:414-420.
• [20]Andre-Schwartz J, Datta SK, Shoenfeld Y, Isenberg DA, Stollar BD, Schwartz RS: Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol 1984, 31:261-271.
• [21]Amital-Teplizki H, Avinoach I, Coates AR, Kooperman O, Blank M, Shoenfeld Y: Binding of monoclonal anti-DNA and anti-TB glycolipids to brain tissue. Autoimmunity 1989, 4:277-287.
• [22]Blank M, Shoenfeld Y: The story of the 16/6 idiotype and systemic lupus erythematosus. Isr Med Assoc J 2008, 10:37-39.
• [23]Isenberg DA, Shoenfeld Y, Madaio MP, Rauch J, Reichlin M, Stollar BD, Schwartz RS: Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet 1984, 2:417-422.
• [24]Galeazzi M, Bellisai F, Sebastiani GD, Morozzi G, Marcolongo R, Houssiau F, Cervera R, Levy Y, George J, Sherer Y, Shoenfeld Y: Association of 16/6 and SA1 anti-DNA idiotypes with anticardiolipin antibodies and clinical manifestations in a large cohort of SLE patients. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol 1998, 16:717-720.
• [25]Amital-Teplizki H, Bearman JE, Miele PW Jr, Sukenik S, Shoenfeld Y: A multidimensional autoantibody analysis specifying systemic lupus erythematosus patients with neuropsychiatric symptomatology. Isr J Med Sci 1992, 28:422-427.
• [26]Isenberg DA, Collins C: Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients. J Clin Invest 1985, 76:287-294.
• [27]Isenberg D, Dudeney C, Wojnaruska F, Bhogal BS, Rauch J, Schattner A, Naparstek Y, Duggan D: Detection of cross reactive anti-DNA antibody idiotypes on tissue-bound immunoglobulins from skin biopsies of lupus patients. J Immunol 1985, 135:261-264.
• [28]Konikoff F, Isenberg DA, Kooperman O, Kennedy RC, Rauch J, Theodor E, Shoenfeld Y: Common lupus anti-DNA antibody idiotypes in chronic liver diseases. Clin Immunol Immunopathol 1987, 43:265-272.
• [29]Shoenfeld Y, Livne A, Blank M, Argov S, Krup M, Fleishmakher E, Sukenik S, Teplizki H: A human monoclonal anti-DNA antibody derived from a patient with polymyositis having the common lupus 16/6 idiotype. Immunol Lett 1988, 19:77-83.
• [30]Mendlovic S, Brocke S, Shoenfeld Y, Ben-Bassat M, Meshorer A, Bakimer R, Mozes E: Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A 1988, 85:2260-2264.
• [31]Shoenfeld Y, Mozes E: Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE. FASEB J 1990, 4:2646-2651.
• [32]Shoenfeld Y: Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994, 8:1296-1301.
• [33]Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E: The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 1995, 7:689-696.
• [34]Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, Pick CG, Leider-Trejo L, Kalashnikova L, Blank M, Chapman J: Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
• [35]Porsolt RD, Bertin A, Jalfre M: Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
• [36]Tordera RM, Totterdell S, Wojcik SM, Brose N, Elizalde N, Lasheras B, Del Rio J: Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007, 25:281-290.
• [37]Dix SL, Aggleton JP: Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. Behav Brain Res 1999, 99:191-200.
• [38]Berry A, Vacirca D, Capoccia S, Bellisario V, Malorni W, Ortona E, Cirulli F: Anti-ATP synthase autoantibodies induce neuronal death by apoptosis and impair cognitive performance in C57BL/6 mice. J Alzheimers Dis 2013, 33:317-321.
• [39]Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT: Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001, 40:750-756.
• [40]Koscec M, Koren E, Wolfson-Reichlin M, Fugate RD, Trieu E, Targoff IN, Reichlin M: Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 1997, 159:2033-2041.
• [41]Matus S, Burgos PV, Bravo-Zehnder M, Kraft R, Porras OH, Farias P, Barros LF, Torrealba F, Massardo L, Jacobelli S, Gonzalez A: Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 2007, 204:3221-3234.
• [42]Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y: Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J Autoimmun 2008, 31:393-398.
• [43]Katzav A, Solodeev I, Brodsky O, Chapman J, Pick CG, Blank M, Zhang W, Reichlin M, Shoenfeld Y: Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 2007, 56:938-948.
• [44]Menachem A, Chapman J, Katzav A: Hyperactivity induced by antiphospholipid syndrome serum. Ann N Y Acad Sci 2009, 1173:422-426.
• [45]Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34:501-537.
• [46]Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G: Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2010, 41:1-11.
• [47]Faust TW, Chang EH, Kowal C, Berlin R, Gazaryan IG, Bertini E, Zhang J, Sanchez-Guerrero J, Fragoso-Loyo HE, Volpe BT, Diamond B, Huerta PT: Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A 2010, 107:18569-18574.
• [48]Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, Volpe BT: Cognition and immunity; antibody impairs memory. Immunity 2004, 21:179-188.
• [49]Kivity S, Tsarfaty G, Agmon-Levin N, Blank M, Manor D, Konen E, Chapman J, Reichlin M, Wasson C, Shoenfeld Y, Kushnir T: Abnormal olfactory function demonstrated by manganese-enhanced MRI in mice with experimental neuropsychiatric lupus. Ann N Y Acad Sci 2010, 1193:70-77.
• [50]Shoenfeld Y, Ben-Yehuda O, Messinger Y, Bentwitch Z, Rauch J, Isenberg DI, Gadoth N: Autoimmune diseases other than lupus share common anti-DNA idiotypes. Immunol Lett 1988, 17:285-291.
• [51]Isenberg DA, Shoenfeld Y: An analysis of autoimmunity through studies of DNA antibody idiotypes. Autoimmunity 1988, 1:67-75.
• [52]El-Roiey A, Gross WL, Luedemann J, Isenberg DA, Shoenfeld Y: Preferential secretion of a common anti-DNA idiotype (16/6 Id) and anti-polynucleotide antibodies by normal mononuclear cells following stimulation with Klebsiella pneumoniae. Immunol Lett 1986, 12:313-319.
• [53]Shoenfeld Y, Vilner Y, Coates AR, Rauch J, Lavie G, Shaul D, Pinkhas J: Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol 1986, 66:255-261.
• [54]Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y: Infections and autoimmunity–friends or foes? Trends Immunol 2009, 30:409-414.
• [55]Broadbent NJ, Squire LR, Clark RE: Spatial memory, recognition memory, and the hippocampus. Proc Natl Acad Sci U S A 2004, 101:14515-14520.
• [56]Milstone AM, Meyers K, Elia J: Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 2005, 24:394-397.
• [57]Mozes E, Sharabi A: A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev 2010, 10:22-26.
• [58]Lapter S, Marom A, Meshorer A, Elmann A, Sharabi A, Vadai E, Neufeld A, Sztainberg Y, Gil S, Getselter D, Chen A, Mozes E: Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis Rheum 2009, 60:3744-3754.
• [59]Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M, Mozes E: Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 2009, 33:77-82.